FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: Results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 498-503

  Taieb J ^a   Lecomte, T ^b   Aparicio, T ^c   Asnacios, A ^a   Mansourbakht, T ^a   Artru, P ^d   Fallik, D ^e   Spano, J P ^a   Landi, B ^b   Lledo, G ^d   Desrame, J ^f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BICHAT HOSPITAL   (France)

^d Clinique Saint Jean   (France)

^e Clinique Jeanne d'Arc   (France)

^f University of Paris Descartes   (France)

Author keywords

Irinotecan; Pancreatic cancer; Systemic chemotherapy

Indexed keywords

APREPITANT; CISPLATIN; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 33847641795     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl427     Document Type: Article

References (45)

1. Faivre J, Forman D, Esteve J et al. Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group. Eur J Cancer 1998; 34: 2184-2190.
2. Fernandez E, La Vecchia C, Porta M et al. Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer 1994; 57: 786-792.
3. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 197-209.
4. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6: 19-28.
5. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
6. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
7. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
8. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167.
9. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902-910.
10. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645.
11. Matsuoka H, Yano K, Seo Y et al. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. Anticancer Drugs 1995; 6: 413-418.
12. Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996; 7: 437-460.
13. Takeda S, Shimazoe T, Sato K et al. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: Detected by RNA/PCR-based quantitation assay. Biochem Biophys Res Commun 1992; 184: 618-625.
14. Sakata Y, Shimada Y, Yoshino M et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer. Gan To Kagaku Ryoho 1994; 21: 1039-1046.
15. Wagener DJ, Verdonk HE, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6: 129-132.
16. Klapdor R, Fenner C. Irinotecan(Campto R): Efficacy as third/fourth line therapy in advanced pancreatic cancer. Anticancer Res 2000; 20: 5209-5212.
17. Ulrich-Pur H, Raderer M, Verena Kornek G et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180-1184.
18. Guichard S, Cussac D, Hennebelle I et al. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997; 73: 729-734.
19. Mans DR, Grivicich I, Peters GJ, Schwartsmann G. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 1999; 35: 1851-1861.
20. Mullany S, Svingen PA, Kaufmann SH, Erlichman C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998; 42: 391-399.
21. Falcone A, Di Paolo A, Masi G et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 3456-3462.
22. Mabro M, Louvet C, Andre T et al. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003; 26: 254-258.
23. Mabro M, Artru P, Andre T et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006; 94: 1287-1292.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987; 71: 1079-1085.
26. Kornmann M, Beger HG, Link KH. Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res 2003; 161: 180-195.
27. Zaman GJ, Lankelma J, van Tellingen O et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-7694.
28. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
29. Rougier P, Zarba JJ, Ducreux M et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993; 4: 333-336.
30. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
31. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783.
32. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
33. Scheithauer W, Schull B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Ann Oncol 2003; 14: 97-104.
34. Heinemann V, Quietzsch D, Gieseler F et al. A phase III trial comparing gemcitabine plus cisplatin versus gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003; 21: 1003 (Abstr 4108).
35. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Can 2005; 4: PS11 (Abstr PS 11).
36. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-8040.
37. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J Clin Oncol 2004; 22: 2610-2616.
38. Conroy T, Paillot B, Francois E et al. Irinotecan plus oxaliplatin and leucovorinmodulated fluorouracil in advanced pancreatic cancer_a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23: 1228-1236.
39. Kozuch P, Grossbard ML, Barzdins A et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6: 488-495.
40. Rocha Lima CM, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-1191.
41. Stathopoulos GP, Rigatos SK, Dimopoulos MA et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: A multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003; 14: 388-394.
42. Klapdor R, Bahlo M, Babinski A et al. Sequential polychemotherapy in exocrine pancreatic cancer. Anticancer Res 2003; 23: 841-844.
43. Oettle H, Arnold D, Hempel C, Riess H. The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 2000; 11: 771-786.
44. Tsavaris N, Kosmas C, Skopelitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23: 369-375.
45. Maisey N, Chau I, Cunningham D et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 20: 3130-3136.